Levo-corydalmine attenuates microglia activation and neuropathic pain by suppressing ASK1-p38 MAPK/NF-κB signaling pathways in rat spinal cord

Abstract

Background and objectivesNeuropathic pain is partially refractory to currently available treatments. Although some studies have reported that apoptosis signal-regulating kinase 1 (ASK1) may inhibit chronic pain, the mechanisms underlying this process have not been fully elucidated.MethodsChronic constriction injury (CCI) of the rat sciatic nerve was used to establish a neuropathic pain model. Nociception was assessed using von Frey hair and Hargreaves’ methods. Western blot and immunofluorescence were used to detect the cell signaling pathway. BV2 cell line was cultured for in vitro evaluation.ResultsOur results indicated that spinal ASK1 was co-expressed with the microglia marker ionized calcium binding adaptor 1. Additionally, intrathecal administration of ASK1 inhibitor suppressed the activation of spinal microglia and attenuated CCI-induced neuropathic pain. The ASK1 inhibitor also decreased the levels of phosphorylated ASK1 (p-ASK1), p65, p38 mitogen-activated protein kinase (MAPK) and tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β) messenger RNA in lipopolysaccharide-stimulated BV2 microglia cells. Intragastric administration of levo-corydalmine (l-CDL) significantly attenuated CCI-induced neuropathic pain and inhibited the expression of p-ASK1 in the spinal cord. l-CDL conspicuously suppressed the activation of spinal microglia in vitro and in vivo. Translocation of nuclearfactor-kappa B (NF-κB) and upregulation of p-p65, TNF-α, IL-1β were inhibited by l-CDL. Further, the analgesic effects of l-CDL were associated with reduced levels of phosphorylated protein kinase C (PKC γ), c-JunNH2-terminal kinase, and extracellular signal-regulated kinase.ConclusionsThis study showed that the expression of ASK1 in spinal microglia and ASK1 inhibitor suppressed microglia activation via suppression of p38 MAPK/NF-κB, which ultimately attenuated CCI-induced neuropathic pain. l-CDL also inhibited the ASK1-P38 MAPK/NF-κB axis to attenuate CCI-induced neuropathic pain.

Rosiglitazone Alleviates Mechanical Allodynia of Rats with Bone Cancer Pain through the Activation of PPAR-γ to Inhibit the NF-κB/NLRP3 Inflammatory Axis in Spinal Cord Neurons

“…Nuclear factor-kappa B (NF- κ B) is a widely studied transcription factor that is involved in many physiological processes, such as regulating multiple aspects of innate and adaptive immune function [ 17 , 18 ], and as a key mediator of the inflammatory response in regulating inflammatory pain [ 19 ], neuropathic pain [ 20 ], and other chronic pain [ 21 ]. Recent studies have shown that NF- κ B participates in the inflammatory cascade by activating the Nod-like receptor protein 3 (NLRP3) inflammasome in the nucleus [ 22 , 23 ].…”

Electroacupuncture may alleviate neuropathic pain via suppressing P2X7R expression

“…Many previous studies have shown that the activation of microglial cells is a key factor in the generation and persistence of neuropathic pain. 34,40 Adenosine triphosphate (ATP) is a transmitter involved in the modulation of traumatic information in the spinal cord. The damaged tissue cells and sensory nerve endings can release a large amount of ATP after peripheral nerve injury.…”

Mogroside V Alleviates Lipopolysaccharide-Induced Neuroinflammation via Inhibition of TLR4-MyD88 and Activation of AKT/AMPK-Nrf2 Signaling Pathway

“…For example, ERK and JNK are mainly expressed in neurons and astrocytes, and p38 MAPK is mainly expressed in microglia [ 34 ]. Previous studies illustrated that the activation of microglia further acts on neurons and astrocytes by promoting secretion of proinflammatory factors [ 35 ]. Our findings also displayed that conditioned media from LPS-treated BV-2 cells significantly weakened the viability of SH-SY5Y cells, while the decline was reversed after the Mog treatment.…”